THERAPEUTIC AREAS

For over twenty years Geneva Romfarm International has been actively, importing, registering, promoting and distributing in Romania, some of the World’s most innovative treatments.
 With a field of expertise ranging from general medicine, to the very specialized tasks of introducing revolutionary drugs for rare diseases, the company is held in the highest regards by the country’s leading physicians, healthcare authorities and patient associations.
We believe that by fostering and maintaining strong ties with patient and professional associations, we achieve an unsurpassed level of feedback from the market that actively plays a role in the way the company acts and reacts to environmental changes.
We also believe in our ethical and civic responsibilities to educate and collaborate with all of our stakeholders.

Geneva Romfarm International created and developed markets for orphan drugs, therapies dedicated to rare diseases as Pulmonary Arterial Hypertension (PAH) and Multiple Sclerosis (MS).

Orphan drugs” are pharmaceutical products intended for prevention or treatment of life-threatening or debilitating rare diseases. They are “orphans” because there is little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.

CARDIOLOGY / PNEUMOLOGY / RARE DISEASES
Pulmonary Arterial Hypertension (PAH)
TRACLEER©
Created and developed local market
Established awareness campaigns for key stakeholders
Formed screening programs to discover misdiagnosed and neglected patients
Key contributor to the creation of a national PAH reimbursement program
OPSUMIT©
Included, since November 2015, in the national PAH reimbursement program

RHEUMATOLOGY / RARE DISEASES
Digital ulcers from scleroderma
TRACLEER©

Created and developed local market
Established awareness campaigns for key stakeholders
Formed screening programs to discover misdiagnosed and neglected patients
Key contributor to the creation of a national digital ulcers reimbursement program

NEURODEGENERATIVE DISEASES
Multiple Sclerosis (MS)
REBIF©
Achieved substantial market share within the 1st year of promotion as one of the best in market therapy
Forged strong bonds with the MS Patient Association.
Key contributor to the creation of a national MS reimbursement program

INFERTILITY
In Vitro Fertilization (IVF)
GONAL-F©, LUVERIS©, CETROTIDE©
Changed prescribers behavior by introducing the first biotech for IVF on the market
Leading Market Position
Key contributor to the creation of a national IVF reimbursement program

INTENSIVE CARE
SEVORANE©, FORANE© (Inhalation Anesthesia)
PROPOFOL©, BUPIVACAINE© (Local Anesthesia)

Market Leader; Introduced a new concept and new guidelines to use vaporized anesthesiology products. Professional collaboration with the society of anesthesiologists (trainings, workshops)
Equipment: Infusion Pumps, Devices, Monitoring Devices

INFECTIOUS DISEASES
KLACID©
Introduced New Generation Macrolides into the market, a powerful tool for physicians activating in the field of IINTERNAL MEDICINE, GASTROENTELOLOGY, PNEUMOLOGY,  OTORHINOLARYNGOLOGY, GENERAL MEDICINE
Major contributor to changing the approach to treating peptic ulcers

PEDIATRICS / NEONATOLOGY
SIMILAC©
Introduced Best and First in Market in products for the nutrition of healthy and sick children
SURVANTA©
Introduced Surfactant for pediatric intensive care
BERACTANT©, PHENEX©, FERROGRADUMET©, VIDAYLIN©
Introduced new products for children

HIV-AIDS
NORVIR©, KALETRA©
Introduced revolutionary treatments with protease inhibitors in Romania and created strong ties to patient associations

PSYCHIATRY
RISPERDAL©, HALDOL©
Active and important presence  on antipsychotic market

DERMATOLOGY
NIZORAL©, RAPTIVA©, SELSUN©

UROLOGY
HYTRIN©
Very active and succesfull presence in the urology field

ENTERAL NUTRITION AND PALLIATIVE CARE ONCOLOGY
PULMOCARE©
Successfully introduced, a high-calorie, low-carbohydrate formula designed to help reduce carbon dioxide production, which is helpful for patients with chronic obstructive pulmonary disease (COPD), cystic fibrosis or respiratory failure